For Research Use Only. Everything on this site is intended solely for laboratory, analytical, or institutional research — not for human or veterinary use, consumption, diagnosis, treatment, or prevention.
New here? Sign up for a one-time 15% welcome code🔥 FALL STACK & SAVE SALE — 20% Off Sitewide · Stacks with WELCOME10 for another 10% · 5% more paying Zelle/Venmo · Through 10/31Volume pricing: 3+ vials save 5%, 6+ vials save 10%Every product's COA is posted on-site, verifiable through the testing lab's own websiteNew here? Sign up for a one-time 15% welcome code🔥 FALL STACK & SAVE SALE — 20% Off Sitewide · Stacks with WELCOME10 for another 10% · 5% more paying Zelle/Venmo · Through 10/31Volume pricing: 3+ vials save 5%, 6+ vials save 10%Every product's COA is posted on-site, verifiable through the testing lab's own website
This page records both labeled components of the current DAAVY Research CJC-1295 + Ipamorelin listing together with its availability and analytical-document status.
The certificate of analysis for this CJC-1295 + Ipamorelin research material was issued by Bioviridian on August 12, 2026. Key results from the report:
Identity
CJC-1295 (no DAC) and Ipamorelin confirmed by LC-MS/MS (conforms)
Purity
99.84% by RP-HPLC at 214 nm (conforms)
Content
5.23 mg and 6.14 mg (5 mg + 5 mg labeled) by HPLC quantitation
This is a two-component peptide laboratory research material. The label identifies CJC-1295 at 5 mg and Ipamorelin at 5 mg, and both amounts are carried consistently across the catalog page and structured product data.
Research background
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), and Ipamorelin is a synthetic pentapeptide that acts as a selective ghrelin-receptor agonist. Published research has evaluated both compounds, individually and in combination, for their effects on growth hormone secretion in clinical and preclinical study settings. This catalog listing has not been evaluated for the purposes described in this research. DAAVY Research supplies this material only for legitimate laboratory, analytical, academic, or institutional research; it is not intended for human or veterinary use, consumption, diagnosis, treatment, or prevention.
Analytical documentation
Third-party COA7573 identifies the sample as CJC-1295 without DAC and Ipamorelin and records identity, component content, and overall purity testing by Bioviridian.
Molecular reference
CJC-1295 (no DAC)
5.23 mg tested · MW 3367.9 g/mol · CAS 863288-34-0
Ipamorelin
6.14 mg tested · MW 711.8 g/mol · CAS 170851-70-4
Overall purity (COA7573)
99.84% by RP-HPLC (214 nm)
Identity method
LC-MS/MS, dual-component confirmation
Component weights and molecular weights are as reported on COA7573 for this specific tested lot; CAS numbers reflect published chemical literature and are provided for research identification purposes only.
Research-use controls
This material is supplied only for legitimate laboratory, analytical, academic, or institutional research. It is not intended for human or veterinary use or consumption, diagnosis, treatment, or prevention.
Frequently asked questions
What does the Certificate of Analysis for CJC-1295 + Ipamorelin cover?
COA7573 documents the identity and analytical testing results reported for this specific tested lot. Review the full report and see our How to Read a COA guide for what each field means before relying on it.
Why are CJC-1295 + Ipamorelin sold together as one listing?
CJC-1295 + Ipamorelin are frequently studied together in peptide research due to their complementary receptor mechanisms, which is why DAAVY Research lists them as a single combined product rather than two separate ones. Each vial's labeled amount for both components is stated on this page and on COA7573.
Is CJC-1295 + Ipamorelin intended for human use?
No. CJC-1295 + Ipamorelin is supplied strictly for laboratory, academic, institutional, or qualified independent research use. It is not for human or veterinary use, consumption, diagnosis, treatment, or prevention.
